Aktienanalyse zu MacroGenics Inc (MGNX)MGNXMacroGenics Inc

MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. It is developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which are referred to as DART and TRIDENT molecules). It has multiple proprietary product candidates. These include three clinical-stage ADCs incorporating a novel topoisomerase I inhibitor (TOP1i)-based linker-payload: MGC026, which targets B7-H3; MGC028, which targets ADAM9, and MGC030, which is directed against an undisclosed target. It is also developing lorigerlimab, a clinical-stage bispecific DART molecule targeting the immune checkpoint receptors PD-1 and CTLA-4. In addition, it is also developing multiple preclinical-stage ADC and next-generation T-cell engager programs. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

MacroGenics Inc is currently trading at $2.33, which is significantly below its 52-week high of $5.08, indicating potential upside. However, the RSI is at a low 27.43, suggesting the stock is oversold, but the forward P/E ratio is very high at 60.98, indicating potential overvaluation. The main risk is the high debt-to-equity ratio of 415.52%, which raises concerns about financial stability.

11 analysts cover MGNX: 9 rate it Buy, 2 Hold and 0 Sell. The average price target is 3.00.